Our Team
Mission
In pursuit of delivering patients the fastest possible visual restoration gene therapy
More than a million patients worldwide with inherited retinal disease are still waiting for an effective treatment that can end their fear of going blind.
Seeing them firsthand, a mission-driven ophthalmologist founded Restore Vision to develop a gene therapy to stop—even reverse—the disease in its tracks.
We can see a future where this too will be a treatable condition. And we want you to see it too.
Executive Leadership
-
Yusaku Katada MD, PhD
CEO/CSO -
Hikaru Miyazaki
COO
Advisers
-
Hitoshi Kawamura PhD
R&D advisor -
Shinichi Koizumi PhD
Executive Advisor -
Tsutomu Uchiyama PhD
IP Strategy Advisor -
Ken Shimokawa PhD
Strategic Advisor -
Andra Miller PhD
CMC Advisor -
Emi Mitsuya
Language Advisor -
Elizabeth K. Messersmith PhD
Consultant, Clinical Dev. and R&D Strategy -
Tetsu Yung PhD MBA
Consultant, Project Management
About Us
Company Name | Restore Vision Inc. |
---|---|
Location |
|
Established | November 14, 2016 |
Representative |
Yusaku Katada MD, PhD Hikaru Miyazaki |
Business Activities | Research and development of regenerative medicine |